| A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors (NCT07769229) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (NCT07763652) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors (NCT07763639) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors (NCT07744243) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan (NCT07730489) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors (NCT07753226) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) (NCT07729956) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) (NCT07739199) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) (NCT07739186) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-08-01 |
| A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) (NCT07642024) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-07-24 |
| A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure (NCT07606599) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-07-07 |
| A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) (NCT07648914) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-07-06 |
| A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (NCT07545460) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer (NCT07654400) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer (NCT07678957) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (NCT07678970) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-07-01 |
| A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) (NCT07582315) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-06-29 |
| A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) (NCT07502300) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-06-15 |
| A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT07606612) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-06-11 |
| A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) (NCT07554456) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-06-09 |
| A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) (NCT07640789) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-06-01 |
| A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment (NCT07518147) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-05-15 |
| A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT07591155) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-05-13 |
| A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes (NCT07591168) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-05-01 |
| A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies (NCT07255898) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-03-25 |
| A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (NCT07255872) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-03-01 |
| A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC (NCT07264816) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-02-03 |
| A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (NCT07279428) | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-01-12 |
| A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (NCT07232524) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-12-10 |
| A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (NCT07274852) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-12-10 |
| A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (NCT07232407) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-11-14 |
| A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors (NCT07232420) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-11-11 |
| A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC (NCT07178795) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-09-29 |
| A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma (NCT07152405) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-09-24 |
| A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer (NCT07054567) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-08-21 |
| A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) (NCT06994195) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-08-04 |
| A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors (NCT07056556) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-07-30 |
| A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer (NCT06962787) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-07-28 |
| A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma (NCT06986785) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-06-24 |
| A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer (NCT06978114) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-06-10 |
| A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer (NCT06891833) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-06-05 |
| A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus (NCT06857214) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-06-04 |
| A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy (NCT06830889) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-06-03 |
| A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer (NCT06957886) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-05-15 |
| A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (NCT06954077) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-05-15 |
| A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) (NCT06857175) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-03-25 |
| A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis (NCT06857227) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-03-17 |
| A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) (NCT06838273) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-02-24 |
| A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT06718621) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-02-12 |
| A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma (NCT06787664) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-01-16 |
| A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies (NCT06718634) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-01-02 |
| A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (NCT06755242) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-01-01 |
| A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma (NCT06423885) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-12-24 |
| A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06668961) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-11-07 |
| A Study of BL-B01D1 in Patients With Recurrent Glioblastoma (NCT06598787) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-10-17 |
| A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors (NCT06612840) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-10-16 |
| A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors (NCT06493864) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-08-26 |
| A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors (NCT06503783) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-08-24 |
| A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) (NCT06500026) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-08-07 |
| A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors (NCT06505824) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-08-02 |
| A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer (NCT06471205) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-08-02 |
| A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT06498986) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-07-31 |
| A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors (NCT06500052) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-07-24 |
| A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT06475131) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-07-18 |
| A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors (NCT06475300) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-06-25 |
| A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) (NCT06382142) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-06-21 |
| A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (NCT06445400) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-06-19 |
| A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer (NCT06437509) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-06-13 |
| A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (NCT06437522) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-06-07 |
| A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (NCT06405425) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-05-29 |
| A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) (NCT06382116) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-05-22 |
| A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) (NCT06382129) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-05-17 |
| A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (NCT06316531) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-05-08 |
| A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer (NCT06114511) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-04-24 |
| A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) (NCT06343948) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-04-24 |
| A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT06349811) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-04-19 |
| A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) (NCT06304974) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-03-19 |
| A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies (NCT06131450) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-02-29 |
| A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors (NCT05956587) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-01-29 |
| A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors (NCT06031584) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-01-19 |
| A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer (NCT06042894) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-12-12 |
| A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors (NCT05965856) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-12-11 |
| A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) (NCT06118333) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-12-04 |
| A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors (NCT06008054) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-11-16 |
| A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies (NCT05990803) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-11-06 |
| A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies (NCT06066203) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-11-01 |
| A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05949606) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-10-30 |
| A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (NCT06006169) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-10-20 |
| A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors (NCT05949619) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-09-04 |
| A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (NCT05944978) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-08-16 |
| A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT05924750) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-08-02 |
| A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05880706) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-07-19 |
| A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma (NCT05943795) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-07-14 |
| A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies (NCT05803018) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-06-25 |
| A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors (NCT05785039) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-04-20 |
| A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL (NCT05627856) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-02-21 |
| A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (NCT05668858) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-02-10 |
| A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) (NCT05485753) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-02-10 |
| Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors (NCT05631964) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-01-05 |
| A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT05623982) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-09-26 |